Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 27:bbab118. doi: 10.1093/bib/bbab118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

The difference of lymphocytes in COVID-19 patients of different genders and their prognostic effects. (A) The proportion of CD3 T cells in PBMC of COVID-19 patients of different genders. (B) The proportion of CD4 T cells in PBMCs of COVID-19 patients of different genders. (C) Proportion of CD8 T cells in PBMC of COVID-19 patients of different genders. (D) Differences in the ratio of CD4/CD8 in PBMC of COVID-19 patients of different genders. (E) Proportion of B cells in PBMC of COVID-19 patients of different genders. (F) The proportion of NK cells in PBMC of COVID-19 patients of different genders. (G) The proportion of Naive B cells in PBMCs of COVID-19 patients of different genders. (H) Proportion of Effector CD8 T cells in PBMC of COVID-19 patients of different genders. Kruskal–Wallis test was used for statistical significance. (I) The cumulative event rate shows that lymphocyte absolute value contributes to the prognosis of all COVID-19 patients. (J) The cumulative event rate shows the contribution of lymphocyte absolute value to the prognosis of male COVID-19 patients. (K) The cumulative event rate shows the contribution of lymphocyte absolute value to the prognosis of female COVID-19 patients. (L) The line chart shows the dynamic changes of lymphocyte absolute value of COVID-19 patients of different genders. With the progress of treatment and the passage of time, multiple test values during the patient’s hospitalization are used for comparison.